Antagonist antibodies to CTLA-4 are in clinical trials to evaluate their anti-tumor efficacy alone and in combination with other therapeutic antibodies, including those targeting the PD-1 and PD-L1 signaling axis [44]. The gene discussed is CTLA4; the disease is neoplasm.